MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

By sjmartinez • November 10, 2023

Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392. PMID: 37945286.

Tags: Ankylosing, Antirheumatic Agents, Arthritis, Psoriatic, Publications, Rheumatoid, Rheumatology, Spondylitis

Serine protease inhibitor, SerpinA3n regulates cardiac remodeling after myocardial infarction

Sun Q, Chen W, Wu R, Tao B, Wang P, Sun B, Alvarez JF, Ma F, Galindo DC, Maroney SP, Saviola AJ, Hansen KC, Li[...]

Cost effectiveness of hepatitis C direct acting agents

Shetty A, Lee M, Valenzuela J, Saab S. Cost effectiveness of hepatitis C direct acting agents. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr 26. doi:[...]

[68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions

Ludwig V, Maliha PG, Shen J, Tonnelet D, Raman S, Litwin MS, Calais J. [68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic[...]